The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway

FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway

(2016) Xiongfei Huang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

(2016) Juan P. Arab et al.   HEPATOLOGY

Bile acids and FGF receptors: orchestrators of optimal liver regeneration

(2015) Hélène Gilgenkrantz et al.   GUT

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma

(2015) Xijun Liu et al.   Oncotarget

Obeticholic acid for the treatment of primary biliary cirrhosis

(2015) Palak J Trivedi et al.   Expert Review of Clinical Pharmacology

Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities

(2014) Christian Gege et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Mechanisms of STAT3 activation in the liver of FXR knockout mice

(2013) Guodong Li et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice

(2013) Guodong Li et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma

(2012) Hongying Su et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Cellular and molecular mechanisms of hepatocellular carcinoma: an update

(2012) Rajagopal N. Aravalli et al.   ARCHIVES OF TOXICOLOGY

FXR ligands protect against hepatocellular inflammation via SOCS3 induction

(2012) Zhizhen Xu et al.   CELLULAR SIGNALLING

Hepatocarcinogenesis in FXR−/−Mice Mimics Human HCC Progression That Operates through HNF1α Regulation of FXR Expression

(2012) Nian Liu et al.   MOLECULAR ENDOCRINOLOGY

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist

(2010) G. Rizzo et al.   MOLECULAR PHARMACOLOGY

Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis

(2010) Morris Sherman   SEMINARS IN LIVER DISEASE

Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling

(2009) Katryn Allen et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY